A. Boon

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

A. Pollard, P. Aley, L. Godfrey, 2022, The Lancet.

THE EFFECT OF THE MEASLES, MUMPS AND RUBELLA VACCINE ON INNATE AND ADAPTIVE IMMUNE RESPONSES IN PERSONS RECEIVING A SARS-COV-2 mRNA VACCINE.A SUB-STUDY OF THE CROWN CORONATION TRIAL

E. Dubberke, S. Khader, S. Thirunavukkarasu, 2022, medRxiv.

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

R. Andino, D. Fremont, M. Diamond, 2021, Nature.

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies

D. Fremont, M. Diamond, J. Crowe, 2021, Research square.

Functional profile of human influenza virus‐specific cytotoxic T lymphocyte activity is influenced by interleukin‐2 concentration and epitope specificity

A. Osterhaus, G. Rimmelzwaan, R. Fouchier, 2005, Clinical and experimental immunology.

In vitro Effect of Bioactive Compounds on Influenza Virus Specific B‐ and T‐Cell Responses

G. Rimmelzwaan, A. P. Vos, Y. Graus, 2002, Scandinavian journal of immunology.